Back to search
FDAFDA · Food and drugs·Recall number Z-0734-2024

FreeStyle Libre 3 App, part of Continuous Glucose Monitoring System, when used on the Android 13 Operating System

Published January 24, 2024 · Recall initiated: February 9, 2023

Summary

FDA records medical device Class II recall Z-0734-2024, published January 24, 2024 and initiated February 9, 2023. Recalling firm: Abbott Diabetes Care, Inc.; Status: Completed; Reported quantity: 45,173; Lot: UDI-DI: 00357599816001, Software v.3.4.0 and below. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

If using affected glucose monitoring app on Android 13 Operating System, extended periods of signal loss may be experienced, due to app not connected, which could impact ability to receive glucose reading/alarms, which could lead to undetected low or high glucose, which could result in delayed treatment: not taking insulin (for high glucose), or not taking glucose (for low glucose) when required.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Abbott Diabetes Care, Inc.
Distributor
US Nationwide distribution in the states of NY, CA, NJ, UT, PA, MS, OH, TX, MN, FL, LA, NE, MI, VA, NC, MA, IN, SC, IA.
Lot
UDI-DI: 00357599816001, Software v.3.4.0 and below
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was FreeStyle Libre 3 App, part of Continuous Glucose Monitoring System, when used on the Android 13 Operating System recalled?

Yes. FDA published recall Z-0734-2024 on January 24, 2024. Reported hazard: If using affected glucose monitoring app on Android 13 Operating System, extended periods of signal loss may be experienced, due to app not connected, which could impact ability to receive glucose reading/alarms, which could lead to undetected low or high glucose, which could result in delayed treatment: not taking insulin (for high glucose), or not taking glucose (for low glucose) when required.

What should I do if I have this product?

Voluntary: Firm initiated · Letter